

May 24, 2026

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
---	---

Dear Sir / Madam,

**Sub: Classification of Unit-I of Eugia Pharma Specialities Limited, Shameerpet (our wholly owned subsidiary) as OAI – Reg.,**

**Ref: Our letter dated February 27, 2026**

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) inspected Unit-I, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Kolthur Village, Shameerpet Mandal, Ranga Reddy, 500078, Telangana, from February 16 to February 27, 2026. The inspection had concluded with 4 observations.

FDA has now determined that the inspection classification of this facility is “official action indicated” (OAI).

The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe. We will keep the stock exchanges informed if there is any further information relating to the above in the future.

Please take the above information on record.

Yours faithfully,

**For AUROBINDO PHARMA LIMITED**

**B. Adi Reddy**  
**Company Secretary**

(CIN : L24239TG1986PLC015190)

**AUROBINDO PHARMA LIMITED**

[www.aurobindo.com](http://www.aurobindo.com)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)

**Annexure**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>
1	Name of the authority	US Food and Drug Administration (US FDA), USA
2	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	The US FDA inspected Unit-I, a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Kolthur Village, Shameerpet Mandal, Ranga Reddy, 500078, Telangana, from February 16 to February 27, 2026. The inspection concluded with 4 observations.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	May 23, 2026.
4	Details of the violation(s)/ contravention(s) committed or alleged to be committed	FDA has now determined that the inspection classification of this facility is “official action indicated” (OAI).
5	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no impact on the Company’s financials or operations due to the said action.

**AUROBINDO PHARMA LIMITED**

[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833

Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)